Genmab and AbbVie’s Epkinly win, a rush of deals, Sarepta’s turnaround hopes, more

0:00-24:18

New data for Genmab and AbbVie’s bispecific antibody Epkinly wowed analysts and could set the partners up for an expanded approval in diffuse large B cell lymphoma; deals have flowed steadily this week, including Novartis’ nearly $8 billion bet on mRNA drugs with China’s Abogen Biosciences; and could Sarepta Therapeutics turn things around from last year’s annus horribilis?

Publisher

BioSpace

Published

October 7, 2026

Duration

24 min

Format

Podcast

Category

Issues · Science

Source

RSS feed

B

BioSpace

@biospace

#genmab #abbviesepkinlywin #sareptasturnaroundhopes #lifesciences

The Nile